Browse PFKL

Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF00365 Phosphofructokinase
Function

Catalyzes the phosphorylation of D-fructose 6-phosphate to fructose 1,6-bisphosphate by ATP, the first committing step of glycolysis (PubMed:22923583). Negatively regulates the phagocyte oxidative burst in response to bacterial infection by controlling cellular NADPH biosynthesis and NADPH oxidase-derived reactive oxygen species. Upon macrophage activation, drives the metabolic switch toward glycolysis, thus preventing glucose turnover that produces NADPH via pentose phosphate pathway (By similarity).

> Gene Ontology
 
Biological Process GO:0002790 peptide secretion
GO:0002791 regulation of peptide secretion
GO:0002792 negative regulation of peptide secretion
GO:0005996 monosaccharide metabolic process
GO:0006002 fructose 6-phosphate metabolic process
GO:0006006 glucose metabolic process
GO:0006007 glucose catabolic process
GO:0006090 pyruvate metabolic process
GO:0006091 generation of precursor metabolites and energy
GO:0006096 glycolytic process
GO:0006165 nucleoside diphosphate phosphorylation
GO:0006732 coenzyme metabolic process
GO:0006733 oxidoreduction coenzyme metabolic process
GO:0006734 NADH metabolic process
GO:0006735 NADH regeneration
GO:0006757 ATP generation from ADP
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009132 nucleoside diphosphate metabolic process
GO:0009135 purine nucleoside diphosphate metabolic process
GO:0009141 nucleoside triphosphate metabolic process
GO:0009144 purine nucleoside triphosphate metabolic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009179 purine ribonucleoside diphosphate metabolic process
GO:0009185 ribonucleoside diphosphate metabolic process
GO:0009199 ribonucleoside triphosphate metabolic process
GO:0009205 purine ribonucleoside triphosphate metabolic process
GO:0009306 protein secretion
GO:0009743 response to carbohydrate
GO:0009746 response to hexose
GO:0009749 response to glucose
GO:0009914 hormone transport
GO:0010817 regulation of hormone levels
GO:0015833 peptide transport
GO:0016052 carbohydrate catabolic process
GO:0019318 hexose metabolic process
GO:0019320 hexose catabolic process
GO:0019362 pyridine nucleotide metabolic process
GO:0019674 NAD metabolic process
GO:0023061 signal release
GO:0030072 peptide hormone secretion
GO:0030073 insulin secretion
GO:0030388 fructose 1,6-bisphosphate metabolic process
GO:0034284 response to monosaccharide
GO:0042278 purine nucleoside metabolic process
GO:0042886 amide transport
GO:0044282 small molecule catabolic process
GO:0044723 single-organism carbohydrate metabolic process
GO:0044724 single-organism carbohydrate catabolic process
GO:0046031 ADP metabolic process
GO:0046034 ATP metabolic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046365 monosaccharide catabolic process
GO:0046496 nicotinamide nucleotide metabolic process
GO:0046676 negative regulation of insulin secretion
GO:0046879 hormone secretion
GO:0046883 regulation of hormone secretion
GO:0046888 negative regulation of hormone secretion
GO:0046939 nucleotide phosphorylation
GO:0050708 regulation of protein secretion
GO:0050709 negative regulation of protein secretion
GO:0050796 regulation of insulin secretion
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051186 cofactor metabolic process
GO:0051224 negative regulation of protein transport
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051262 protein tetramerization
GO:0051289 protein homotetramerization
GO:0061615 glycolytic process through fructose-6-phosphate
GO:0061620 glycolytic process through glucose-6-phosphate
GO:0061621 canonical glycolysis
GO:0061718 glucose catabolic process to pyruvate
GO:0072524 pyridine-containing compound metabolic process
GO:0090087 regulation of peptide transport
GO:0090276 regulation of peptide hormone secretion
GO:0090278 negative regulation of peptide hormone secretion
GO:1901657 glycosyl compound metabolic process
GO:1903531 negative regulation of secretion by cell
GO:1904950 negative regulation of establishment of protein localization
Molecular Function GO:0003872 6-phosphofructokinase activity
GO:0008443 phosphofructokinase activity
GO:0019200 carbohydrate kinase activity
GO:0030246 carbohydrate binding
GO:0048029 monosaccharide binding
GO:0070061 fructose binding
GO:0070095 fructose-6-phosphate binding
Cellular Component GO:0005945 6-phosphofructokinase complex
GO:0044445 cytosolic part
GO:0061695 transferase complex, transferring phosphorus-containing groups
> KEGG and Reactome Pathway
 
KEGG hsa03018 RNA degradation
hsa04066 HIF-1 signaling pathway
hsa04152 AMPK signaling pathway
hsa04922 Glucagon signaling pathway
hsa00010 Glycolysis / Gluconeogenesis
hsa00030 Pentose phosphate pathway
hsa00051 Fructose and mannose metabolism
hsa00052 Galactose metabolism
hsa01100 Metabolic pathways
hsa01200 Carbon metabolism
hsa01230 Biosynthesis of amino acids
Reactome R-HSA-70326: Glucose metabolism
R-HSA-70171: Glycolysis
R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-71387: Metabolism of carbohydrates
R-HSA-6798695: Neutrophil degranulation
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between PFKL and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of PFKL in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of PFKL in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0640.766
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1550.955
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2230.912
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.5210.186
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.3680.889
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7160.832
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0330.937
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0570.975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0340.987
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2540.907
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5830.857
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1460.0536
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of PFKL in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.44.13.30.61
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.45.12.30.647
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.26.2160.53
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 475014.335.70.491
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of PFKL. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of PFKL. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by PFKL.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of PFKL. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of PFKL expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between PFKL and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolPFKL
Namephosphofructokinase, liver
Aliases PFK-B; PFK-L; 6-phosphofructokinase type B; 6-phosphofructokinase, liver type; liver-type 1-phosphofructokin ......
Chromosomal Location21q22.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting PFKL collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.